Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88


Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.

Scherer EM, Zwick MB, Teyton L, Burton DR.

AIDS. 2007 Oct 18;21(16):2131-9.


Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L; CAPRISA 002 Study Team..

J Virol. 2007 Jun;81(12):6187-96.


An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB.

J Virol. 2007 Apr;81(8):4033-43.


Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1.

Huang JH, Lu L, Lu H, Chen X, Jiang S, Chen YH.

J Biol Chem. 2007 Mar 2;282(9):6143-52.


Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.

Cardoso RM, Brunel FM, Ferguson S, Zwick M, Burton DR, Dawson PE, Wilson IA.

J Mol Biol. 2007 Feb 2;365(5):1533-44.


Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Zhang MY, Choudhry V, Sidorov IA, Tenev V, Vu BK, Choudhary A, Lu H, Stiegler GM, Katinger HW, Jiang S, Broder CC, Dimitrov DS.

J Immunol Methods. 2006 Dec 20;317(1-2):21-30.


Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.

Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, Autran B, Barin F.

AIDS. 2006 Oct 3;20(15):1923-30.


Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Günthard HF.

Antimicrob Agents Chemother. 2006 May;50(5):1773-9.


HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.

Bower JF, Li Y, Wyatt R, Ross TM.

Vaccine. 2006 Jun 29;24(26):5442-51.


Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody.

Sánchez-Martínez S, Lorizate M, Hermann K, Kunert R, Basañez G, Nieva JL.

FEBS Lett. 2006 Apr 17;580(9):2395-99.


Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.

J Virol. 2006 Mar;80(6):3030-41.


Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, Corcoran P, Zwick MB, Franti M, Morris L, Roux KH, Burton DR, Binley JM.

J Virol. 2006 Mar;80(5):2515-28.


Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, Dawson PE.

J Virol. 2006 Feb;80(4):1680-7.


Antibody vs. HIV in a clash of evolutionary titans.

Burton DR, Stanfield RL, Wilson IA.

Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):14943-8. Review.


Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC.

J Virol. 2005 Aug;79(16):10108-25.


Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC.

J Virol. 2005 Aug;79(16):10103-7. No abstract available.


Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF.

Nat Med. 2005 Jun;11(6):615-22.


Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM.

Science. 2005 Jun 24;308(5730):1906-8.

Supplemental Content

Support Center